Anvatabart opadotin

奥丁安妥拜单抗

Report date: 2026/05/15 20:01:45

Base Information

Drug NameAnvatabart opadotin
Drug Alias Name重组人源化抗HER2单抗-AS269偶联Antibody-drug conjugate (Ambrx/Zhejiang Medicine)ARX-788NCB-001JNJ-0683
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Amberstatin269 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized +[4] 
Mechanisms of ActionTubulin inhibitorsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsTubulinReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandAustralia +[6] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAmbrx Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhejiang Xinma Biomedicine Co LtdFudan UniversityAmbrx Inc +[6] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A